Physician profile

Paul W Huser

Family Medicine · Wichita, KS

NPI 1730140708

$8,357.43

in general payments reported to CMS, 2019-2025

43 companies · $1,040 in 2025

The $1,040 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).

See the full distribution for Family Medicine

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,983.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $1,597.54 2019-2025 Airsupra, Farxiga, Breztri
Abbvie INC. $738.01 2019-2025
Amgen INC. $737.28 2019-2025 Evenity, Prolia, Otezla
Pfizer INC. $708.68 2019-2025
Novo Nordisk INC $554.04 2019-2025 Ozempic, Rybelsus, Wegovy
Lilly USA, LLC $515.42 2021-2025 Mounjaro, Jardiance, Emgality
Boehringer Ingelheim Pharmaceuticals, INC. $495.89 2019-2025 Jardiance, Ofev
Janssen Pharmaceuticals, INC $277.04 2019-2022
Amarin Pharma, INC. $252.22 2019-2022
Astellas Pharma US INC $198.94 2019-2021
Merck Sharp & Dohme LLC $197.13 2019-2021
Medtronic, INC. $190.95 2021-2025 Intellis Adaptivestim, Symplicity G3
Sumitomo Pharma America, INC. $146.42 2023-2025 Gemtesa
Grifols USA, LLC $144.74 2024-2025 Prolastin-C Liquid
Biohaven Pharmaceuticals, INC. $134.23 2021
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $126.54 2019-2025
Biohaven Pharmaceutical Holding Company LTD. $122.32 2022
Eisai INC. $121.39 2020-2022
Abbott Laboratories $104.68 2021-2025 Freestyle Libre 3
Daiichi Sankyo INC. $103.50 2020-2022
Bayer Healthcare Pharmaceuticals INC. $93.14 2021-2022
Takeda Pharmaceuticals U.S.A., INC. $86.79 2019-2022
Dexcom, INC. $77.16 2024-2025 Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $75.24 2022-2023 Xifaxan, Trulance
Nevro Corp. $68.04 2022-2023 Senza
Allergan, INC. $60.95 2020-2021
Sunovion Pharmaceuticals INC. $57.51 2019-2021
E.R. Squibb & Sons, L.L.C. $38.48 2021-2022
Electromed, INC. $33.28 2021
Glaxosmithkline, LLC. $30.28 2019-2023 Arexvy
Exact Sciences Corporation $27.63 2024-2025 Cologuard Collection Kit
Sanofi-Aventis U.S. LLC $25.50 2019-2021
Vanda Pharmaceuticals INC. $24.14 2025 Fanapt
Kowa Pharmaceuticals America, INC. $24.03 2020-2022
Genentech USA, INC. $23.56 2019
Esperion Therapeutics, INC. $23.26 2021
Sanofi Pasteur INC. $22.38 2025
Cranial Technologies, INC $20.61 2024 Doc Band
Inspire Medical Systems, INC. $18.77 2023 Inspire
Pacira Therapeutics, INC. $16.33 2020
Abiomed $15.76 2025
Shire North American Group INC $14.55 2019
Idorsia Pharmaceuticals US INC $13.08 2023 Quviviq

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Paul W Huser

$8,357.43

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $1,040 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/697718/paul-w-huser

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.